{
    "clinical_study": {
        "@rank": "50282", 
        "acronym": "TENDENCY", 
        "arm_group": [
            {
                "arm_group_label": "Chemo plus Endostar", 
                "arm_group_type": "Experimental", 
                "description": "Docetaxel, epirubicin and cyclophosphamide plus endostar"
            }, 
            {
                "arm_group_label": "Chemo only", 
                "arm_group_type": "Active Comparator", 
                "description": "docetaxel, epirubicin and cyclophosphamide"
            }
        ], 
        "brief_summary": {
            "textblock": "The trial was designed to study the efficacy and safety of neoadjuvant docetaxel, epirubicin\n      in combination with cyclophosphamide(DEC) plus human recombinant endostatin (endostar) for\n      breast cancer patients. The hypothesis of this protocol is that the combined an active\n      angiogenesis agent to chemotherapy could enhance the pathological responce rate and further\n      benefit breast cancer patients."
        }, 
        "brief_title": "A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Stage III Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed invasive breast cancer (core needle biopsy for breast cancer\n             diagnosis and fine needle aspiration for lymph node metastasis diagnosis)\n\n          -  Age 18-70\n\n          -  No evidence of distant metastasis\n\n          -  No previous therapy\n\n          -  Normal hematologic function\n\n          -  No abnormality of renal or liver function\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  With allergic constitution or possible allergic reflection to drugs to be used in\n             this study\n\n          -  Any concurrent uncontrolled medical or psychiatric disorder\n\n          -  History of severe heart diseases, including congestive heart failure, unstable\n             angina, uncontrolled arrhythmia, myocardial infarction, uncontrolled high blood\n             pressure, or heart valve disease\n\n          -  Being pregnant or nursing"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01907529", 
            "org_study_id": "HBMUFH-101"
        }, 
        "intervention": [
            {
                "arm_group_label": "Chemo only", 
                "description": "docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; totally 4 cycles", 
                "intervention_name": "docetaxel, epirubicin and cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Chemo plus Endostar", 
                "description": "docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostar 7.5mg/m2, IV (in the vein) from day 1 to day 14, totally 4 cycles", 
                "intervention_name": "docetaxel, epirubicin and cyclophosphamide plus endostar", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Docetaxel", 
                "Epirubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 22, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Trail of Neoadjuvant Endostar in Combination With Docetaxel, Epirubicin and Cyclophosphamide in Patients With Stage III Breast Cancer (TENDENCY)", 
        "overall_contact": {
            "email": "lyj818326@126.com", 
            "last_name": "Yunjiang Liu, M.D", 
            "phone": "12703297890"
        }, 
        "overall_official": {
            "affiliation": "Hebei Medical University Fourth Hospital", 
            "last_name": "YUNJIANG LIU, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The clincial response will be evaluated according to RECIST criteria.", 
            "measure": "Clinical/pathological response", 
            "safety_issue": "No", 
            "time_frame": "48 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01907529"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hebei Medical University Fourth Hospital", 
            "investigator_full_name": "Yunjiang Liu", 
            "investigator_title": "M.D, Chief Physician of Breast Cancer Dept, Vice-President of Hebei Medical University Fourth Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "PFS", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "source": "Hebei Medical University Fourth Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hebei Medical University Fourth Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}